Biogen Launches $5.6B Tender Offer to Acquire Apellis for $41/Share Plus CVRs
APLS has more than doubled off its 52-week low of $16.1 on elevated volume (22× avg).
Summary
Biogen Inc. has commenced a tender offer to acquire Apellis Pharmaceuticals, Inc. for approximately $5.6 billion, offering $41.00 per share in cash plus contingent value rights.
Key Events · M&A and Partnerships · APLS
-
Tender Offer Commenced
Biogen Inc., through its subsidiary Aspen Purchaser Sub, Inc., has initiated a tender offer to acquire all outstanding shares of Apellis Pharmaceuticals, Inc.
-
Acquisition Terms Announced
The offer is for $41.00 per share in cash, plus contingent value rights (CVRs) tied to future global sales of SYFOVRE. The total upfront consideration is approximately $5.6 billion.
-
Strategic Rationale Detailed
Biogen aims to enhance its immunology and rare disease portfolio with Apellis's SYFOVRE and EMPAVELI products, and accelerate its expansion into nephrology by leveraging Apellis's infrastructure for its felzartamab launch.
-
Expected Financial Impact
Biogen expects the transaction to be increasingly accretive starting in 2027 and to meaningfully increase its non-GAAP diluted EPS CAGR through 2030.
Analysis · APLS · Life Sciences
This SC TO-C filing formally announces the commencement of Biogen's tender offer to acquire Apellis Pharmaceuticals, Inc., following earlier news and concurrent 8-K and SC14D9C filings. The acquisition, valued at approximately $5.6 billion, represents a significant premium over Apellis's recent trading price and fundamentally alters the company's future. For Apellis shareholders, this offers a clear exit at a premium, with potential upside from CVRs. For Biogen, the deal is expected to bolster its growth portfolio with two commercialized medicines, SYFOVRE and EMPAVELI, and strategically expand its presence in nephrology, leveraging Apellis's existing infrastructure for future product launches like felzartamab. Investors should monitor the tender offer's progress and the integration plans, particularly regarding the commercialization strategies for SYFOVRE and EMPAVELI and the realization of anticipated synergies.
At the time of this filing, APLS was trading at $40.35 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.2B. The 52-week trading range was $16.10 to $40.45. This filing was assessed with positive market sentiment and an importance score of 10 out of 10.